Adiponectin relation to skin changes and dyslipidemia in systemic sclerosis

Area of Science:

• Endocrinology and Metabolism
• Rheumatology
• Immunology

Background:

• Adiponectin is a key regulator of metabolic homeostasis.
• Emerging evidence links adiponectin to inflammatory, rheumatic, vascular, and fibrotic diseases.
• Systemic sclerosis (SSc) is a complex autoimmune disease with significant fibrotic manifestations.

Purpose of the Study:

• To investigate circulating adiponectin levels in patients with systemic sclerosis (SSc).
• To explore the association between adiponectin and skin manifestations in SSc.
• To characterize the relationship between adiponectin and other SSc-related features.

Main Methods:

• Serum adiponectin was measured in 39 SSc patients and 30 healthy controls using ELISA.
• Other markers included IL-6, sIL-2R, lipids, CRP, ANA, ENA, and urinary pyridinoline.
• Skin involvement was quantified using the modified Rodnan skin score.

Main Results:

• Serum adiponectin levels were comparable between SSc patients and healthy controls (p=0.670).
• A significant negative correlation was observed between serum adiponectin and the modified Rodnan skin score (r=-0.379, p=0.017).
• Regression models indicated that adiponectin, HDL-cholesterol, CRP, skin score, disease duration, and age influenced outcomes.

Conclusions:

• Adiponectin levels are similar in SSc patients and controls.
• Adiponectin may exert a protective effect against skin and atherosclerosis-related complications in SSc.
• Further research is warranted to elucidate adiponectin's precise role in SSc pathogenesis.